Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marlieke de Vos"'
Autor:
Delphine Issard, Nicola De Stefano, Mark S. Freedman, Marlieke de Vos, Giancarlo Comi, Liang Chen, Bernard M. J. Uitdehaag, Kurt Marhardt, Ludwig Kappos, Frederik Barkhof
Publikováno v:
Comi, G, Stefano, N D, Freedman, M S, Barkhof, F, Uitdehaag, B M J, de Vos, M, Marhardt, K, Chen, L, Issard, D & Kappos, L 2017, ' Subcutaneous interferon ß-1a in the treatment of clinically isolated syndromes : 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 88, no. 4, pp. 285–294 . https://doi.org/10.1136/jnnp-2016-314843
Journal of Neurology, Neurosurgery and Psychiatry, 88(4). BMJ Publishing Group
Journal of Neurology, Neurosurgery and Psychiatry, 88(4). BMJ Publishing Group
Objective Early treatment following a first clinical demyelinating event (FCDE) delays further disease activity in patients with multiple sclerosis (MS). This study determined the effects of early versus delayed treatment (DT) with subcutaneous inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f3117ba7558557231fea0dde464731
https://research.vumc.nl/en/publications/0bdedeb3-f38e-47d3-8574-5d995962c0ae
https://research.vumc.nl/en/publications/0bdedeb3-f38e-47d3-8574-5d995962c0ae
Autor:
Marlieke de Vos, Nancy Richert, Mike P. Wattjes, Petur Snaebjornsson, Frederik Barkhof, Joep Killestein, Diego Cadavid, Esther Sanchez
Publikováno v:
Wattjes, M P, Richert, N D, Killestein, J, de Vos, M L, Sanchez, E, Snæbjörnsson, P, Cadavid, D & Barkhof, F 2013, ' The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy ', Multiple Sclerosis, vol. 19, no. 14, pp. 1826-1840 . https://doi.org/10.1177/1352458513510224
Multiple Sclerosis, 19(14), 1826-1840. SAGE Publications Ltd
Multiple Sclerosis, 19(14), 1826-1840. SAGE Publications Ltd
Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side
Autor:
Martijn D. Steenwijk, Dorine A M Siepman, Jop P. Mostert, Marlieke de Vos, Nancy Richert, Mike P. Wattjes, Wiebe Moll, Frederik Barkhof, Anke Vennegoor, Alex E L van Golde, Joep Killestein, Bob W. van Oosten, S. T. F. M. Frequin
Publikováno v:
Journal of Neurology, Neurosurgery and Psychiatry, 86(7), 793-798. BMJ Publishing Group
Journal of Neurology Neurosurgery and Psychiatry, 86(7), 793-798. BMJ Publishing Group
Wattjes, M P, Vennegoor, A, Steenwijk, M D, Vos, M, Killestein, J, van Oosten, B W, Mostert, J, Siepman, D A, Moll, W, van Golde, A E L, Frequin, S T F M, Richert, N D & Barkhof, F 2015, ' MRI pattern in asymptomatic natalizumab-associated PML ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 86, no. 7, pp. 793-798 . https://doi.org/10.1136/jnnp-2014-308630
Journal of Neurology Neurosurgery and Psychiatry, 86(7), 793-798. BMJ Publishing Group
Wattjes, M P, Vennegoor, A, Steenwijk, M D, Vos, M, Killestein, J, van Oosten, B W, Mostert, J, Siepman, D A, Moll, W, van Golde, A E L, Frequin, S T F M, Richert, N D & Barkhof, F 2015, ' MRI pattern in asymptomatic natalizumab-associated PML ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 86, no. 7, pp. 793-798 . https://doi.org/10.1136/jnnp-2014-308630
Objective: To investigate the MRI manifestation pattern of asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS). Methods: 18 patients with MS with natalizumab-associated PML les
Autor:
Frederik Barkhof, Klaus Wagner, Marlieke de Vos, Ludwig Kappos, Lars Bauer, Chris H. Polman, Xavier Montalban, S Dahms, Rupert Sandbrink, Mark S. Freedman, Peter A. Poppe, Ernst-Wilhelm Radue, Christoph Pohl, Fatiha Lasri, Gilles Edan, Hans-Peter Hartung, David Miller
Publikováno v:
Archives of neurology. 64(9)
In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent brain magnetic